Biotech Values

[Titan V]

EDGE (-85% /PM) Ph3 Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation of Study #FAIL

$EDGE Ph3 Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation of Study #FAIL

— Andy Biotech (@AndyBiotech) March 28, 2018